L
Lauren M. Cane
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 8
Citations - 1036
Lauren M. Cane is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: FOLFIRI & FOLFOX. The author has an hindex of 6, co-authored 8 publications receiving 965 citations.
Papers
More filters
Journal ArticleDOI
KIT as a therapeutic target in metastatic melanoma
Richard D. Carvajal,Cristina R. Antonescu,Jedd D. Wolchok,Paul B. Chapman,Ruth-Ann Roman,Jerrold B. Teitcher,Katherine S. Panageas,Klaus J. Busam,Bartosz Chmielowski,Jose Lutzky,Anna C. Pavlick,Anne Fusco,Lauren M. Cane,Naoko Takebe,Swapna S. Vemula,Nancy Bouvier,Boris C. Bastian,Gary K. Schwartz +17 more
TL;DR: Among patients with advanced melanoma harboring KIT alterations, treatment with imatinib mesylate results in significant clinical responses in a subset of patients, indicating positive selection for the mutated allele.
Journal ArticleDOI
A Phase I Clinical Trial of Safingol in Combination with Cisplatin in Advanced Solid Tumors
Mark A. Dickson,Richard D. Carvajal,Alfred H Merrill,Mithat Gonen,Lauren M. Cane,Gary K. Schwartz +5 more
TL;DR: Reversible dose-dependent hepatic toxicity was seen, as expected from preclinical data, and safingol, the first putative SphK inhibitor to enter clinical trials, can be safely administered in combination with cisplatin.
Journal ArticleDOI
A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT
Richard D. Carvajal,Paul B. Chapman,Jedd D. Wolchok,Lauren M. Cane,Jerrold B. Teitcher,Jose Lutzky,Anna C. Pavlick,Boris C. Bastian,C. R. Antonescu,Gary K. Schwartz +9 more
TL;DR: While IM has limited activity in a non-selected melanoma pt population, a substantial proportion of melanomas harboring KIT mut or amp appear to respond and it may be possible to identify appropriate pts prospectively for treatment with IM.
Journal ArticleDOI
Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors
Dana E. Rathkopf,Mark A. Dickson,Darren R. Feldman,Richard D. Carvajal,Manish A. Shah,Nian Wu,Robert A. Lefkowitz,Mithat Gonen,Lauren M. Cane,H. Dials,Jennifer L. Winkelmann,George J. Bosl,Gary K. Schwartz +12 more
TL;DR: Encouraging results in the platinum-refractory germ cell tumor population has prompted a phase II trial that is currently open for accrual, and Flavopiridol with FOLFOX is a safe and tolerable regimen.
Journal ArticleDOI
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors
Mark A. Dickson,Dana E. Rathkopf,Richard D. Carvajal,Steven Grant,John D. Roberts,Joel M. Reid,Matthew M. Ames,Renee M. McGovern,Robert A. Lefkowitz,Mithat Gonen,Lauren M. Cane,H. Dials,Gary K. Schwartz +12 more
TL;DR: Intermittent high dose oral V in combination with flavopiridol is feasible and achieves target serum levels >2.5 µM, which is higher than previously reported with oral dosing.